Werewolf Therapeutics, Inc. business relationships
Companies named in Werewolf Therapeutics, Inc.’s 10-K filed 2026-03-27, and public companies whose annual reports name Werewolf Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 6% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Werewolf Therapeutics, Inc.’s annual report 3
“JZP898: IFNα INDUKINE Molecule Licensed Globally to Jazz Pharmaceuticals Ireland Limited” SEC filing
“Collaboration and License Agreement, dated as of April 6, 2022, by and between the Registrant and Jazz Pharmaceuticals Ireland Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 10, 2022, File...” SEC filing
“For example, in April 2022, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha, or IFNα, IN...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.